Track Charles River Laboratories International, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Charles River Laboratories International, Inc. CRL · Stock Open Charles River Laboratories International, Inc. in new tab

337.97 USD
P/E
367.36
EPS
0.92
P/B
5.01
ROE
1.27
Beta
1.34
Target Price
350.57 USD
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc.

🧾 Earnings Recap – Q1 2026

Charles River’s shares declined 2.3% following the Q1 earnings, reflecting investor caution amid ongoing portfolio restructuring and a cautious outlook on margin expansion despite announced cost savings and strategic divestitures.

  • Delivered $100 million in incremental cost savings this year above 2025 levels, targeting $300 million in annualized savings from recent initiatives.
  • Completed acquisitions to secure non-human primates supply and enhance next-generation sequencing capabilities supporting biologics testing.
  • Divested CDMO and Cell Solutions businesses, with additional European discovery site sales planned, focusing on core drug development testing strengths.
  • Initiatives expected to contribute to future margin expansion, though near-term performance and guidance left the market hesitant.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 17, 2027
P/E367.36
EPS0.92
Book Value67.40
Price to Book5.01
Debt/Equity87.08
% Insiders1.508%
Growth
Revenue Growth-0.02%
Earnings Growth5.24%
Estimates
Forward P/E26.06
Forward EPS12.97
Target Mean Price350.57

DCF valuation

Model fair value for Charles River Laboratories International, Inc. (CRL)
Result
Sign in to run the valuation for CRL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Buy · mean target 350.57 USD (low 145.00, high 400.00) · as of 15 Nov 2026
Low 145.00
Mean 350.57
High 400.00
Price 337.97
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Charles River Laboratories International, Inc. Logo Charles River Laboratories International, Inc. Analysis (CRL)

United States Health Care Official Website Stock

Is Charles River Laboratories International, Inc. a good investment? Charles River Laboratories International, Inc. (CRL) is currently trading at 337.97 USD. Market analysts have a consensus price target of 350.57 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 367.36. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Charles River Laboratories International, Inc. is expected to release its next earnings report on Feb. 17, 2027. The market consensus estimate for Forward EPS is 12.97.

Investor FAQ

Does Charles River Laboratories International, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Charles River Laboratories International, Inc.?

Charles River Laboratories International, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 17, 2027. The company currently has a trailing EPS of 0.92.

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exchange Ticker
GER (Germany) RV6.DE
FRA (Germany) RV6.F
NYQ (United States) CRL
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion